Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launched

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

WASHINGTON-Marshall Edwards, Inc. has launched a multi-center phase II clinical trial of its anticancer drug phenoxodiol in women with recurrent ovarian and fallopian tube cancers who have failed other forms of chemotherapy.

WASHINGTON—Marshall Edwards, Inc. has launched a multi-center phase II clinical trial of its anticancer drug phenoxodiol in women with recurrent ovarian and fallopian tube cancers who have failed other forms of chemotherapy.

A damaged cell normally shuts off production of the antiapoptotic proteins FLIP and XIAP to allow activation of the apoptosis-triggering receptors (Fas, TNFR1, DR3, TRAIL). Cancer cells resist this process by producing large amounts of blocking proteins such as FLIP. Phenoxodiol blocks FLIP and XIAP in cancer cells without harming noncancer cells, the company said in a news release.

Articles in this issue
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launched
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLC
Most Cancer Pain Is Experienced at the Patient’s Home
HHS Unites Its HIV Advisors
First NCI Health Disparity Grants
Pain Therapy Improves Quality of Life for Caregivers
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Mice
Safe Handling Tips for Use of Testosterone Gel
Lumpectomy/Mastectomy Equivalent in Early Breast Cancer
New Agent Tested in Refractory and Relapsed Ovarian Cancer
HIV Testing of Pregnant Women Increases: CDC Report
Targeted Home Nursing Visits Post Breast Surgery Cost-Effective
IRIS Trial Update Confirms Imatinib Advantage in CML
Elderly Vulnerable to Febrile Neutropenia Early in Chemotherapy
Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content
Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Immune Priming Strategies Numerically Improve PFS in Ovarian Cancer

Roman Fabbricatore
November 24th 2025
Article

Although both immune priming strategies numerically improved ORR and PFS vs olaparib monotherapy, the study was not powered for comparisons between arms.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Roman Fabbricatore
November 14th 2025
Article

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

Roman Fabbricatore
October 28th 2025
Article

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report

Prosper Akankwasa, MBBS;Jackson Kakooza, MBBS;Aisha Abdullahi Ahmed, MBBS;Catherine R. Lewis, MD, PhD
October 28th 2025
Article

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.